Clemons M, Danson S, Howell A
Division of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5.
Cancer Treat Rev. 2002 Aug;28(4):165-80. doi: 10.1016/s0305-7372(02)00036-1.
Tamoxifen has been used in the management of breast cancer for over 30 years. Since its introduction for the treatment of advanced breast cancer, its indications have increased to include the treatment of early breast cancer, ductal carcinoma in situ, and more recently for breast cancer chemoprevention. Tamoxifen has a good tolerability profile and moreover, unlike many other endocrine therapies, it is efficacious in both pre- and postmenopausal women. It is the combination of efficacy and tolerability that allows tamoxifen to maintain its position as the hormonal treatment of choice for most patients with oestrogen-receptor positive breast cancer. Ongoing studies will provide further information about the optimal duration of tamoxifen therapy and how it compares with the newer aromatase inhibitors.
他莫昔芬用于乳腺癌治疗已有30多年。自被引入用于治疗晚期乳腺癌以来,其适应证已扩大至包括早期乳腺癌、原位导管癌,以及最近用于乳腺癌化学预防。他莫昔芬具有良好的耐受性,而且与许多其他内分泌疗法不同,它在绝经前和绝经后女性中均有效。正是疗效和耐受性的结合,使他莫昔芬能够保持其作为大多数雌激素受体阳性乳腺癌患者首选激素治疗的地位。正在进行的研究将提供有关他莫昔芬治疗最佳疗程的更多信息,以及它与新型芳香化酶抑制剂相比的情况。